Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

@article{Holden2005ClinicalEO,
  title={Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.},
  author={Scott N. Holden and S. Gail Eckhardt and Russell Basser and Richard de Boer and Danny Rischin and Michael Green and Mark Andrew Rosenthal and C. C. Wheeler and Alan J. Barge and Herbert I. Hurwitz},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 8},
  pages={1391-7}
}
BACKGROUND ZD6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor and epidermal growth factor receptor. The safety, tolerability and pharmacokinetics of ZD6474 were assessed in a phase I dose-escalation study of patients with advanced solid tumors. PATIENTS AND METHODS Adult patients with tumors refractory to standard treatments received once-daily oral ZD6474 (50-600 mg) in 28-day cycles, until disease progression or unacceptable toxicity was… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS